163 results about "Chemical Injury" patented technology

The invention relates to a kind of compound collagen protein gutta, which is the mixture of collagen protein and antibiotics. For every 100ml compound collagen gutta, there is 10-500mg collagen protein which is extracted from the tendon, 100-600mg antibiotics which include one or two kinds of the following antibiotics: ofloxacin, alficetin, tenebrimycin, while the rest is the iso-osmia, which is 5% amylaceum solution. The product has three main functions: resist bacteria and inflammation; help to keep the eyeball moist, promote the agglutination and relieve the asthenopia; be used in the treatment of the damage to the cornea, keratohelcosis, keratitis punctata, slight chemical injury to cornea as well as the thermal damage to the cornea; prevent the ophthalmia and relieve the asthenopia; prevent the cohesive property of the collagen from being diluted so as to extend the effective time of the gutta; resist the bacteria as well as promote the agglutination.

The present invention provides a method of using agents which can modulate TRPA1 function as counteragents to inhibit the physical effects of chemical irritants/toxicants when given prior to exposure or to lessen the physical effects when administered post exposure, and more specifically, to a method for counteracting the acute physical noxious effects of toxicants, including but not limited to, tear gases, chlorine, hydrogen peroxide, ammonia, phosgene, chloropicrin, isocyanates and mustard gas. Administering the counteragents counteracts pain, inflammation, lachrymation, blepharospasm, respiratory irritation and depression, airway mucus secretion, airway obstruction and injury, cough and incapacitation and cutaneous chemical injuries. Another embodiment provides a method of preventing or treating a disease or condition in a mammal, which disease or condition includes hypersensitivity to chemical stimuli, particularly in regards to inflammatory airway conditions, such as asthma, rhinitis, etc., by administering to the mammal a therapeutically effective amount of a compound that inhibits TRPA1 function, wherein the compound reduces the hypersensitivity and mediates the response to such chemical stimuli in the mammal. The invention also includes a kit containing the compound that inhibits the TRPA1 function as a counteracting agent for administration prior to or post exposure to prevent or limit the effects of the exposure.